Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Research & Development of $27.6 million for Q1 2026, up 24.82% year-over-year from $22.1 million in Q1 2025, and up 30.16% quarter-over-quarter from $21.2 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Research & Development history runs 6 years deep, the most recent figure standing at $27.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 24.82% year-over-year to $27.6 million; the TTM figure through Mar 2026 stood at $95.9 million (up 7.03% YoY), while the FY2025 annual figure was $90.4 million, down 13.14% from the prior year.
- Research & Development for Q1 2026 stood at $27.6 million, up from $21.2 million in the prior quarter.
- The five-year high for Research & Development was $44.9 million in Q4 2023, with the low at $19.9 million in Q3 2025.
- The 5-year median for Research & Development is $24.2 million (2023), against an average of $26.1 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development jumped 212.7% in 2022, then tumbled 49.03% in 2024.
- Amylyx Pharmaceuticals' Research & Development stood at $22.8 million in 2022, then surged by 96.88% to $44.9 million in 2023, then plunged by 49.03% to $22.9 million in 2024, then retreated by 7.33% to $21.2 million in 2025, then jumped by 30.16% to $27.6 million in 2026.
- Business Quant data shows AMLX's Research & Development at $27.6 million in Q1 2026, $21.2 million in Q4 2025, and $19.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 173.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | - |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 92.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | 23.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.77 Mn |
| Mar 31, 2026 | 27.61 Mn |
| Dec 31, 2025 | 21.21 Mn |
| Sep 30, 2025 | 19.86 Mn |
| Jun 30, 2025 | 27.22 Mn |
| Mar 31, 2025 | 22.12 Mn |
| Dec 31, 2024 | 22.89 Mn |
| Sep 30, 2024 | 21.24 Mn |
| Jun 30, 2024 | 23.35 Mn |
| Mar 31, 2024 | 36.61 Mn |
| Dec 31, 2023 | 44.91 Mn |
| Sep 30, 2023 | 30.04 Mn |
| Jun 30, 2023 | 29.04 Mn |
| Mar 31, 2023 | 24.19 Mn |
| Dec 31, 2022 | 22.81 Mn |
| Sep 30, 2022 | 24.91 Mn |
| Jun 30, 2022 | 24.26 Mn |
| Mar 31, 2022 | 21.46 Mn |
| Dec 31, 2021 | 13.39 Mn |
| Sep 30, 2021 | 12.85 Mn |